187-POS

Abstract

Objectives Preeclampsia (PE) is a severe complication of pregnancy characterized by an excessive maternal systemic inflammatory response with activation of the immune system. However, few therapeutic options exist aside from delivery. In treating variety of diseases, CsA exertits positive effects by immunosuppressive role. The aim of the study was to test the hypothesis that Cyclosporin A attenuate inflammatory response on a preeclampsia model. Methods Using a low dose of lipopolysaccharide (LPS, 1.0 μg/kg) on gestational day (GD) 14 to induced preeclampsia (PE) rat model. CsA was administrated by 5 mg/kg or 10 mg/kg on day of 16, 17, 18 of pregnancy based on the PE model. Then we compared blood pressure,urinary albumin,biometric parameters (ALT, AST, SCr, BUN) and the levels of serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17, TNF- α , IFN- γ ) before and after we suppressed the inflammatory response by Cyclosporin A (CsA) in two doses. Results After LPS treatment, the systolic blood pressure (SBP) was significantly higher on GD16 (p α and IFN- γ , as well as T helper-17 (Th17)-type inflammatory cytokine IL-17 in the PE group. These levels decreased following CsA administration. The serum T helper-2 (Th2)-type inflammatory cytokine IL-4 was decreased in the PE group, and elevated (p Conclusions The current study suggests that effect of cyclosporine is achieved by attenuate a Th1/Th2/Th17 imbalance, which may be involved in the pathogenesis of preeclampsia. Disclosures B. Hu: None. H. Liu: None. Q. Huang: None. J. Yang: None. Y. Jiang: None. J. Bao: None. S.P. Brennecke: None.